Latest Conference Articles

The SKYSCRAPER-14 trial did not show a PFS benefit with tiragolumab plus atezolizumab and bevacizumab in untreated HCC, missing its coprimary end point.

212Pb-DOTAMTATE Yields Responses and Shows Disease Control in Pretreated Advanced GEP-NETS

October 19th 2025, 8:15pm

212Pb-DOTAMTATE produced responses with a manageable safety profile in patients with SSTR-positive, PRRT-exposed, unresectable or metastatic GEP-NETs.

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC

October 19th 2025, 8:14pm

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC

October 19th 2025, 8:05pm

Sirexatamab plus bevacizumab shows promise in improving survival for patients with DKK1-high metastatic colorectal cancer.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

October 19th 2025, 7:40pm

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC

October 19th 2025, 7:32pm

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

October 19th 2025, 7:25pm

Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

October 19th 2025, 7:11pm

ESMO Congress: Head and Neck Cancer

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Enfortumab Vedotin Plus Pembrolizumab Shows First-Line Activity in PD-L1+ Recurrent/Metastatic HNSCC

October 19th 2025, 7:11pm

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Dr Hurvitz on Sustained Benefit With Adjuvant Ribociclib Plus AI Therapy in HR+/HER2– Breast Cancer

October 19th 2025, 6:36pm

ESMO Congress: Breast Cancer

Sara A. Hurvitz, MD, FACP, shares 5-year efficacy updates from the phase 3 NATALEE trial in HR-positive HER2-negative breast cancer.

Dr Mayer on Efficacy Data With Giredestrant Plus Everolimus in ER+/HER2– Breast Cancer

October 19th 2025, 6:32pm

ESMO Congress: Breast Cancer

Erica L. Mayer, MD, MPH, discusses primary efficacy outcomes for giredestrant in the phase 3 evERA trial in ER-positive, HER2-negative advanced breast cancer.

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma

October 19th 2025, 6:19pm

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025, 6:05pm

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Atezolizumab Plus Chemotherapy Demonstrates Noninferior Survival Vs Chemotherapy Alone in Advanced/Recurrent Endometrial Cancer

October 19th 2025, 5:55pm

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer

October 19th 2025, 4:36pm

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025, 3:46pm

ESMO Congress: Breast Cancer

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

Sacituzumab Govitecan Reduces Risk of Progression or Death by 38% in PD-1/PD-L1–Ineligible TNBC

October 19th 2025, 2:25pm

Sacituzumab govitecan reduced the risk for disease progression or death by 38% vs chemotherapy in previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer.

Capivasertib Plus Abiraterone Acetate, Prednisone, and ADT Extends rPFS in PTEN-Deficient HSPC

October 19th 2025, 2:16pm

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

TUB-040 Yields Responses Across Dose Levels in Platinum-Resistant High-Grade Serous Ovarian Cancer

October 19th 2025, 1:49pm

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer

October 19th 2025, 1:47pm